Research Technological Partnership: PITE-FAPESP Consortium

The São Paulo Research Foundation (FAPESP), Drugs for Neglected Diseases initiative (DNDi), Medicines for Malaria Venture (MMV), University of São Paulo (USP) and University of Campinas (UNICAMP) invite you to the launch of the project

Research Partnership for Technological Innovation (PITE-FAPESP)
to discover novel drug candidates for the treatment
of parasitic tropical diseases

November 28th, 2019 • 9:30 – 11:05 • FAPESP

The event will present the PITE FAPESP Consortium to be based at the University of Campinas (UNICAMP). The project will be carried out in partnership with the leading institutions mentioned above. The ultimate goal is to discover new drug candidates for clinical development in the treatment of parasitic tropical diseases.

Registration: www.fapesp.br/eventos/consortium/registration


09:30 Registration
10:00 Opening



Carlos Henrique de Brito Cruz – Scientific Director (FAPESP)


New Drugs for Neglected Diseases

Charles Mowbray – Discovery Director (DNDi) Download


Drug Discovery to Control and Eradicate Malaria

Paul Willis – Senior Director, Drug Discovery (MMV) Download


Science for All: Urgent Needs

Sylvio Canuto – Dean of Research (USP)


Are Malaria, Chagas Disease and Leishmaniasis Neglected
Diseases? Not at UNICAMP

Daniel Martins de Souza – Assistant to the Dean of Research (UNICAMP) Download


Drug Discovery for the Most Neglected

Luiz Carlos Dias – Coordinator of the PITE-FAPESP Consortium (UNICAMP) Download

11:05 Closing

Through the project and working with expert scientists from MMV the team will focus on delivering a candidate to treat malaria.

The compound should have the potential to be developed, in combination, to deliver a single exposure radical cure and prophylaxis or single exposure chemoprotection drug. MMV will provide quality lead molecules, aligned to a particular target product profile (TPP) of interest.

The goal of the project with DNDi is to deliver an optimized lead compound ready for preclinical and subsequently clinical development for the treatment of Chagas disease and/or leishmaniasis that addresses the significant deficiencies of current standard of care medications.

The Consortium will use the target product profiles (TPPs) developed by DNDi and its partners to ensure the deliverable is a compound that meets the needs of patients. The targeted clinical candidate will combine anti-protozoal efficacy with an acceptable safety profile and pharmacokinetics/physicochemical properties commensurate with oral delivery for testing against Chagas disease and leishmaniasis.

FAPESP – Rua Pio XI, 1500 – Alto da Lapa – São Paulo

Information – 11.3838-4362 | eventos@fapesp.br

Parking suggestion – Rua Pio XI, 1650 | Av. São Gualter, 151 Rua Jorge Americano, 89